Bone Biologics
BBLG
7 hedge funds and large institutions have $235K invested in Bone Biologics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
17% more funds holding
Funds holding: 6 → 7 (+1)
2.37% less ownership
Funds ownership: 12.93% → 10.56% (-2.4%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
59% less capital invested
Capital invested by funds: $576K → $235K (-$341K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.5K |
| 2 |
MML Investors Services
Springfield,
Massachusetts
|
+$15.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$644 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$149 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$72K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$38.3K |
| 3 |
Walleye Capital
New York
|
-$25.6K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$15.5K |
| 5 |
VF
Virtu Financial
New York
|
-$4.85K |
BBLG Hedge Fund Activity: Q3 2023 in Review
7 of the 6,312 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q3 2023, worth a combined $235K — down 59% from $576K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BBLG positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $16.5K. The largest seller was Kepos Capital, exiting entirely with an estimated $72K sold.
- 7 institutional investors held Bone Biologics (BBLG) as of Q3 2023, up from 6 in Q2 2023.
- Funds reported $235K of Bone Biologics stock for Q3 2023, down 59% quarter-over-quarter.
- 4 funds opened new Bone Biologics positions in Q3 2023 and 3 closed out, a net change of +1 holder.
- The largest Bone Biologics buyer in Q3 2023 was Geode Capital Management, an estimated $16.5K added.
- The largest Bone Biologics seller in Q3 2023 was Kepos Capital, an estimated $72K sold.
Based on aggregated 13F filings for Q3 2023.